

Naoto T Ueno

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/2474462/publications.pdf](https://exaly.com/author-pdf/2474462/publications.pdf)

Version: 2025-02-01

324
papers

16,988
citations

12994

63
h-index

14565

119
g-index

496
all docs

496
docs citations

496
times ranked

27453
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice?. <i>Cancers</i> , 2025, 17, 884.	4.0	1
2	Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. <i>JCO Precision Oncology</i> , 2024, , .	2.1	3
3	Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. <i>Clinical Cancer Research</i> , 2024, 30, 2424-2432.	6.4	0
4	ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors. <i>Cancer Research Communications</i> , 2024, 4, 2415-2426.	3.0	0
5	Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. <i>Cancer Research Communications</i> , 2024, 4, 2823-2834.	3.0	3
6	Differences in Breast Cancer Subtypes among Racial/Ethnic Groups. <i>Cancers</i> , 2024, 16, 3462.	4.0	0
7	Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer. <i>Npj Precision Oncology</i> , 2024, 8, .	6.9	0
8	Stabilization of E-cadherin adhesions by COX-2/GSK3 β signaling is a targetable pathway in metastatic breast cancer. <i>JCI Insight</i> , 2023, 8, .	5.5	17
9	Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. <i>Biomedicines</i> , 2023, 11, 735.	3.6	1
10	Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2023, 15, 1616.	4.0	7
11	Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer. <i>Cancer Research Communications</i> , 2023, 3, 1078-1092.	3.0	2
12	Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. <i>Cancers</i> , 2023, 15, 3275.	4.0	9
13	Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment. <i>Journal of the National Cancer Institute</i> , 2022, 114, 97-108.	5.1	15
14	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. <i>Npj Breast Cancer</i> , 2022, 8, .	6.8	6
15	A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer. <i>Scientific Reports</i> , 2022, 12, .	3.7	4
16	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	2.1	16
17	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1323.	4.0	10
18	Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling. <i>Nature Communications</i> , 2022, 13, .	14.1	9

#	ARTICLE	IF	CITATIONS
19	NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 579-591.	5.1	29
20	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2878-2889.	6.4	17
21	Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 405-425.	3.9	3
22	Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. <i>Annals of Surgical Oncology</i> , 2022, , .	1.7	3
23	An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1449-1461.	1.7	20
24	A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System. <i>Cancers</i> , 2022, 14, 5238.	4.0	27
25	EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. <i>Science Advances</i> , 2022, 8, .	11.3	28
26	Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy. <i>Seminars in Ultrasound, CT and MRI</i> , 2021, 42, 164-183.	1.9	2
27	Update on systemic treatment for newly diagnosed inflammatory breast cancer. <i>Journal of Advanced Research</i> , 2021, 29, 1-12.	10.9	25
28	Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 296-306.	1.7	20
29	Body composition and breast cancer risk and treatment: mechanisms and impact. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 273-283.	2.5	58
30	Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. <i>Communications Biology</i> , 2021, 4, .	4.5	45
31	Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase. <i>JCO Oncology Practice</i> , 2021, 17, 177-183.	3.4	19
32	The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 4265-4274.	1.7	16
33	The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 608.	4.0	10
34	Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 32, 116013.	2.7	12
35	Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. <i>PLoS ONE</i> , 2021, 16, e0250057.	2.5	4
36	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. <i>Genome Medicine</i> , 2021, 13, .	9.9	13

#	ARTICLE	IF	CITATIONS
37	Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer. <i>Cancers</i> , 2021, 13, 2650.	4.0	12
38	PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. <i>Biomedicines</i> , 2021, 9, 740.	3.6	10
39	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. <i>Breast Cancer Research and Treatment</i> , 2021, , .	2.5	7
40	Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. <i>Nature Communications</i> , 2021, 12, .	14.1	151
41	Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 8610-8621.	1.7	8
42	Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 333-345.	2.5	4
43	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5365-5375.	6.4	41
44	Inflammatory Breast Cancer at the Extremes of Age. <i>Annals of Surgical Oncology</i> , 2021, 28, 5626-5634.	1.7	5
45	Inflammatory breast cancer appearance at presentation is associated with overall survival. <i>Cancer Medicine</i> , 2021, 10, 6261-6272.	2.8	12
46	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. <i>Molecular Oncology</i> , 2021, 15, 2752-2765.	4.2	23
47	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 4839.	4.0	24
48	Estrogen Receptor β -Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. <i>Cancer Research</i> , 2021, 81, 2399-2414.	0.6	10
49	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Oncimmunology</i> , 2021, 10, .	5.6	28
50	ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells. <i>Biomedicines</i> , 2021, 9, 1410.	3.6	10
51	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. <i>Scientific Reports</i> , 2021, 11, .	3.7	13
52	Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases. <i>World Journal of Oncology</i> , 2021, 12, 183-194.	1.6	2
53	“Why and What” for the optimal management of inflammatory breast cancer. <i>Chinese Clinical Oncology</i> , 2021, 10, 54-54.	1.4	0
54	Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. <i>Cancer Medicine</i> , 2020, 9, 1025-1032.	2.8	18

#	ARTICLE	IF	CITATIONS
55	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020, 14, 504-519.	4.2	26
56	Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 579-586.	5.1	15
57	The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 ⁻) metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 729-739.	2.5	2
58	Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4603-4612.	1.7	13
59	Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. <i>Cancers</i> , 2020, 12, 3105.	4.0	2
60	Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. <i>JCO Clinical Cancer Informatics</i> , 2020, , 839-853.	2.4	14
61	Targeting Signaling Pathways in Inflammatory Breast Cancer. <i>Cancers</i> , 2020, 12, 2479.	4.0	22
62	NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. <i>Cancers</i> , 2020, 12, 3711.	4.0	21
63	Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. <i>JCO Clinical Cancer Informatics</i> , 2020, , 583-601.	2.4	5
64	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. <i>BMC Cancer</i> , 2020, 20, .	3.0	5
65	The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer. <i>Journal of Pathology</i> , 2020, 251, 63-73.	5.2	15
66	Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. <i>Cells</i> , 2020, 9, 515.	4.8	5
67	Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. <i>Oncologist</i> , 2020, 25, e909-e919.	3.6	2
68	Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. <i>Cancer Research</i> , 2020, 80, 1304-1315.	0.6	45
69	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. <i>PLoS ONE</i> , 2020, 15, e0231953.	2.5	19
70	JNK Signaling in Stem Cell Self-Renewal and Differentiation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2613.	4.5	62
71	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream [®] in patients with breast cancer treated with primary systemic therapy. <i>PLoS ONE</i> , 2020, 15, e0229903.	2.5	25
72	Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1588-1595.	0.9	22

#	ARTICLE	IF	CITATIONS
73	Inflammatory breast cancer cells are characterized by abrogated TGF β 21-dependent cell motility and SMAD3 activity. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 385-395.	2.5	14
74	Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. <i>Scientific Reports</i> , 2020, 10, .	3.7	35
75	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, .	3.8	44
76	Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. <i>Journal of Cancer</i> , 2019, 10, 3344-3351.	2.7	20
77	Patient reported outcomes can improve performance status assessment: a pilot study. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, .	2.6	24
78	Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. <i>PLoS ONE</i> , 2019, 14, e0222336.	2.5	18
79	Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. <i>Practical Radiation Oncology</i> , 2019, 9, 402-409.	2.6	10
80	The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. <i>Journal of Cancer</i> , 2019, 10, 2635-2642.	2.7	4
81	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. <i>British Journal of Cancer</i> , 2019, 120, 1105-1112.	5.7	26
82	Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 545-556.	2.5	20
83	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1025-1035.	3.7	76
84	Imaging features of triple-negative breast cancers according to androgen receptor status. <i>European Journal of Radiology</i> , 2019, 114, 167-174.	3.1	12
85	Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 339-351.	2.5	20
86	Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 399-412.	1.7	9
87	Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model. <i>Oncologist</i> , 2019, 24, 1322-1330.	3.6	7
88	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019, 37, 345-351.	2.6	29
89	Bone Metastasis of Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, , 105-129.	0.0	97
90	Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 615-623.	2.5	14

#	ARTICLE	IF	CITATIONS
91	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018, 124, 2299-2305.	4.4	11
92	Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. <i>American Journal of Clinical Pathology</i> , 2018, 149, 253-261.	0.6	22
93	Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. <i>Cancer</i> , 2018, 124, 866-866.	4.4	0
94	Inflammatory breast cancer biology: the tumour microenvironment is key. <i>Nature Reviews Cancer</i> , 2018, 18, 485-499.	24.2	240
95	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. <i>Human Pathology</i> , 2018, 77, 121-129.	2.4	20
96	The Emerging Impact of Social Media on Cancer Patient Education in Japan. <i>Oncologist</i> , 2018, 23, e105-e106.	3.6	2
97	Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e73-e77.	2.4	30
98	<i>BRCA</i> mutations in women with inflammatory breast cancer. <i>Cancer</i> , 2018, 124, 466-474.	4.4	13
99	Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. <i>European Journal of Cancer</i> , 2018, 89, 64-71.	3.3	3
100	Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2018, , 1-15.	2.1	48
101	<i>ST8SIA1</i> Regulates Tumor Growth and Metastasis in TNBC by Activating the <i>FAK</i> – <i>AKT</i> – <i>mTOR</i> Signaling Pathway. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2689-2701.	1.7	71
102	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. <i>PLoS ONE</i> , 2018, 13, e0204372.	2.5	17
103	Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. <i>PLoS ONE</i> , 2018, 13, e0204513.	2.5	36
104	Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. <i>Journal of Cancer</i> , 2018, 9, 3640-3646.	2.7	20
105	Inflammatory Breast Cancer. <i>Surgical Clinics of North America</i> , 2018, 98, 787-800.	2.2	74
106	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. <i>Clinical Biomechanics</i> , 2018, 56, 61-69.	1.4	5
107	<i>CSF-1/CSF-1R</i> axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. <i>Scientific Reports</i> , 2018, 8, .	3.7	31
108	Survivorship and Advocacy in Inflammatory Breast Cancer. <i>Journal of Cancer</i> , 2018, 9, 1430-1436.	2.7	5

#	ARTICLE	IF	CITATIONS
109	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. <i>Journal of Cancer</i> , 2018, 9, 1437-1447.	2.7	90
110	Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. <i>Clinical Breast Cancer</i> , 2018, 18, e1283-e1288.	2.4	10
111	Reply to "A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18". <i>Breast</i> , 2018, 39, 148-149.	2.6	2
112	Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. <i>PLoS ONE</i> , 2018, 13, e0195932.	2.5	16
113	Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, .	3.8	4
114	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1207.	13.6	61
115	Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. <i>Oncogene</i> , 2018, 38, 2135-2150.	6.6	29
116	Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 501-511.	2.5	11
117	Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. <i>Oncotarget</i> , 2018, 9, 6872-6882.	1.7	8
118	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>British Journal of Cancer</i> , 2017, 116, 509-514.	5.7	17
119	Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 463-479.	4.1	41
120	Identification of frequent somatic mutations in inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 263-272.	2.5	30
121	Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. <i>Cancer</i> , 2017, 123, 2422-2431.	4.4	19
122	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 57-67.	2.5	33
123	Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4780-4792.	6.4	35
124	Novel therapeutic strategies in the treatment of triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 493-511.	3.8	57
125	Inflammatory breast cancer: a proposed conceptual shift in the UICC/AJCC TNM staging system. <i>Lancet Oncology</i> , 2017, 18, e228-e232.	21.9	77
126	Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1266.	13.6	166

#	ARTICLE	IF	CITATIONS
127	Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. <i>Cancer</i> , 2017, 123, 2618-2625.	4.4	10
128	Reply to "Comment on "Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy". <i>British Journal of Cancer</i> , 2017, 116, e11-e11.	5.7	0
129	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718.	40.1	192
130	Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. <i>Cancer Medicine</i> , 2017, 6, 2515-2522.	2.8	28
131	Thrombocytosis as a prognostic factor in inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 819-832.	2.5	18
132	Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. <i>Annals of Surgical Oncology</i> , 2017, 24, 2981-2988.	1.7	33
133	Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2017, 19, .	5.0	47
134	In response to "outcomes of patients with inflammatory breast cancer treated by breast conserving surgery": the argument against breast conservation and sentinel lymph node biopsy in IBC. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 779-781.	2.5	4
135	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10 th Anniversary Conference. <i>Journal of Cancer</i> , 2017, 8, 3607-3614.	2.7	13
136	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. <i>Journal of Cancer</i> , 2017, 8, 2004-2009.	2.7	15
137	Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors. <i>PLoS ONE</i> , 2017, 12, e0170081.	2.5	6
138	Androgen receptor expression on circulating tumor cells in metastatic breast cancer. <i>PLoS ONE</i> , 2017, 12, e0185231.	2.5	19
139	Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. <i>Journal of Cancer</i> , 2017, 8, 1726-1732.	2.7	4
140	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. <i>Journal of Cancer</i> , 2017, 8, 1045-1052.	2.7	8
141	MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2017, 489, 484-489.	2.1	7
142	Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells. <i>Molecular Therapy - Oncolytics</i> , 2017, 6, 1-9.	5.1	27
143	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 35656-35668.	1.7	42
144	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 14897-14911.	1.7	39

#	ARTICLE	IF	CITATIONS
145	EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 67904-67917.	1.7	37
146	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. <i>Oncotarget</i> , 2017, 8, 70481-70495.	1.7	14
147	A target of potential RELAvance in inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 25835-25836.	1.7	0
148	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. <i>Journal of Cancer</i> , 2016, 7, 947-956.	2.7	8
149	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. <i>Oncologist</i> , 2016, 21, 21-27.	3.6	19
150	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw026.	5.1	63
151	Neoadjuvant nab-paclitaxel in the treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 427-440.	2.5	19
152	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54.	40.1	1,561
153	Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 101-109.	2.5	13
154	Impact of clinical trial on survival outcomes. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 273-281.	2.5	4
155	Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. <i>Carcinogenesis</i> , 2016, , bgw097.	2.9	20
156	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12780-12785.	7.7	30
157	Epidemiological risk factors associated with inflammatory breast cancer subtypes. <i>Cancer Causes and Control</i> , 2016, 27, 359-366.	1.8	40
158	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. <i>Modern Pathology</i> , 2016, 29, 330-346.	5.0	34
159	MIR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 791-799.	0.7	24
160	Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. <i>Oncotarget</i> , 2016, 7, 82482-82492.	1.7	81
161	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <i>Oncotarget</i> , 2016, 7, 76362-76373.	1.7	22
162	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. <i>Oncotarget</i> , 2016, 7, 18531-18540.	1.7	36

#	ARTICLE	IF	CITATIONS
163	Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. <i>Oncotarget</i> , 2016, 7, 28329-28339.	1.7	56
164	Inflammatory and Locally Advanced Breast Cancer. , 2016, , 411-435.		0
165	Prognosis for patients with metastatic breast cancer who achieve a noâ€videnceâ€ofâ€disease status after systemic or local therapy. <i>Cancer</i> , 2015, 121, 4324-4332.	4.4	38
166	Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 242-247.	1.4	28
167	Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2015, 6, 1306-1319.	2.7	17
168	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. <i>Journal of Cancer</i> , 2015, 6, 310-318.	2.7	18
169	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. <i>Oncotarget</i> , 2015, 6, 12890-12908.	1.7	93
170	Disulfiram (DSF) acts as a copper ionophore to induce copperâ€dependent oxidative stress and mediate antiâ€tumor efficacy in inflammatory breast cancer. <i>Molecular Oncology</i> , 2015, 9, 1155-1168.	4.2	185
171	Targeted Therapies in Triple-Negative Breast Cancer: Failure and Future. <i>Women's Health</i> , 2015, 11, 1-5.	1.6	9
172	Circulating tumor cells in newly diagnosed inflammatory breast cancer. <i>Breast Cancer Research</i> , 2015, 17, .	5.0	36
173	Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 458-466.	2.4	10
174	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 407-416.	2.5	71
175	High-Density and Very-Low-Density Lipoproteinâ€Have Opposing Roles in Regulating Tumor-Initiating Cells and Sensitivity to Radiation in Inflammatory Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 1072-1080.	0.7	33
176	Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. <i>Breast Cancer Research</i> , 2015, 17, .	5.0	50
177	Challenging a Traditional Paradigm. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 262e-269e.	2.0	21
178	Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1311.	13.6	73
179	Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv250.	5.1	24
180	MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2773-2781.	1.7	64

#	ARTICLE	IF	CITATIONS
181	Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. <i>American Journal of Clinical Pathology</i> , 2015, 144, 713-721.	0.6	29
182	Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2687-2699.	1.7	18
183	Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 495-508.	2.5	53
184	Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. <i>Cancer Letters</i> , 2015, 356, 374-381.	8.5	10
185	Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers. <i>Clinical Breast Cancer</i> , 2015, 15, 37-42.	2.4	6
186	Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0132710.	2.5	87
187	Challenges and perspective of drug repurposing strategies in early phase clinical trials. <i>Oncoscience</i> , 2015, 2, 576-580.	1.6	41
188	Functional consequence of the <i>MET-T</i> 1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015, 6, 2604-2614.	1.7	37
189	High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e83113.	2.5	76
190	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 745-753.	2.7	42
191	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014, 16, .	5.0	91
192	Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database. <i>Journal of Clinical Oncology</i> , 2014, 32, 2018-2024.	17.1	111
193	Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. <i>Cancer</i> , 2014, 120, 1319-1328.	4.4	59
194	Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5265-5271.	6.4	29
195	Reverse-Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer. <i>Oncologist</i> , 2014, 19, 909-914.	3.6	13
196	Aldehyde Dehydrogenase 1 Expression in Inflammatory Breast Cancer as Measured by Immunohistochemical Staining. <i>Clinical Breast Cancer</i> , 2014, 14, e81-e88.	2.4	16
197	Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. <i>Stem Cells Translational Medicine</i> , 2014, 3, 849-856.	3.6	70
198	The Role of Inflammation in Inflammatory Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014, , 53-73.	0.0	48

#	ARTICLE	IF	CITATIONS
199	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, .	11.5	24
200	A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 259-272.	2.5	41
201	Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. <i>SpringerPlus</i> , 2014, 3, .	1.7	20
202	Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. <i>Cancer</i> , 2014, 120, 1775-1779.	4.4	8
203	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. <i>Cell Reports</i> , 2014, 7, 488-500.	6.4	40
204	18F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1809-1816.	5.4	18
205	TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. <i>Cancer Research</i> , 2013, 73, 6516-6525.	0.6	70
206	Latest biopsy approach for suspected metastases in patients with breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 711-719.	25.3	23
207	Breast Cancer Biomarkers: Utility in Clinical Practice. <i>Current Breast Cancer Reports</i> , 2013, 5, 284-292.	0.9	17
208	A Comparison of Epidemiology, Biology, and Prognosis of Inflammatory Breast Cancer in Japanese and US Populations. <i>Clinical Breast Cancer</i> , 2013, 13, 460-464.	2.4	11
209	A Prospective Study of Bone Tumor Response Assessment in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 24-30.	2.4	34
210	Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. <i>Breast Cancer Research</i> , 2013, 15, .	5.0	48
211	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. <i>Clinical Cancer Research</i> , 2013, 19, 4685-4696.	6.4	120
212	Genomic and expression analysis of microdissected inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 761-772.	2.5	47
213	Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1099-1111.	1.7	14
214	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. <i>Clinical Cancer Research</i> , 2013, 19, 5533-5540.	6.4	570
215	Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. <i>Journal of Cancer</i> , 2013, 4, 679-685.	2.7	3
216	Novel Functional Assay for Spindle-Assembly Checkpoint by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient. <i>Journal of Cancer</i> , 2013, 4, 697-702.	2.7	4

#	ARTICLE	IF	CITATIONS
217	The Anthelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e71508.	2.5	43
218	Bone Metastasis of Breast Cancer. , 2013, , 189-209.		0
219	Signaling Pathways in Inflammatory Breast Cancer. , 2012, , 151-160.		0
220	Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2012, 30, 729-734.	17.1	228
221	Epithelialâ€“Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2526-2534.	1.7	183
222	Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. <i>Leukemia and Lymphoma</i> , 2012, 53, 1239-1241.	1.6	16
223	Metastasis in the Breast Mimicking Inflammatory Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e202-e206.	17.1	6
224	Phase II Study of Gonadotropin-Releasing Hormone Analog for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients. <i>Oncologist</i> , 2012, 17, 233-238.	3.6	24
225	MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15â€“Dependent Manner in a Mouse Xenograft Model. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 360-369.	1.7	21
226	Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 593-599.	17.1	346
227	Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. <i>Journal of Cancer</i> , 2012, 3, 369-380.	2.7	59
228	Inflammatory Breast Cancer: What We Know and What We Need to Learn. <i>Oncologist</i> , 2012, 17, 891-899.	3.6	124
229	Role of epidermal growth factor receptor in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 331-345.	2.5	562
230	Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 264-269.	2.4	89
231	Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients With Inflammatory Breast Cancer Influences Radiation Treatment Field Designs. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1381-1386.	0.7	42
232	Microfluidics separation reveals the stem-cellâ€“like deformability of tumor-initiating cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18707-18712.	7.7	181
233	Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/â€“Catenin Signaling. <i>Stem Cells</i> , 2012, 30, 2366-2377.	3.3	93
234	Bone Metastases. , 2012, , 591-609.		2

#	ARTICLE	IF	CITATIONS
235	Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with boneâ€œonly metastases. <i>Cancer</i> , 2012, 118, 2039-2047.	4.4	17
236	Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 137, 523-531.	2.5	22
237	Systemic and Targeted Therapy. , 2012, , 85-99.		0
238	Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study. , 2012, , 225-242.		0
239	High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Inflammatory Breast Cancer. , 2012, , 127-138.		0
240	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011, 13, .	5.0	181
241	Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. <i>Journal of Cancer</i> , 2011, 2, 435-442.	2.7	23
242	Targeting EGFR in Triple Negative Breast Cancer. <i>Journal of Cancer</i> , 2011, 2, 324-328.	2.7	126
243	Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27. <i>Gynecologic Oncology</i> , 2011, 122, 641-647.	1.6	19
244	Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. <i>International Journal of Clinical Oncology</i> , 2011, 16, 596-600.	2.4	9
245	Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early. <i>Cancer</i> , 2011, 117, 1819-1826.	4.4	118
246	Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. <i>Cancer</i> , 2011, 117, 5476-5484.	4.4	59
247	Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. <i>International Journal of Cancer</i> , 2011, 129, 417-423.	4.5	97
248	Initial Staging Impact of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Locally Advanced Breast Cancer. <i>Oncologist</i> , 2011, 16, 772-782.	3.6	16
249	Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer. <i>Oncologist</i> , 2011, 16, 956-965.	3.6	9
250	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1873.	13.7	497
251	High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 3214-3223.	17.1	83
252	Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. <i>Oncologist</i> , 2011, 16, 1675-1683.	3.6	82

#	ARTICLE	IF	CITATIONS
253	High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 3224-3231.	17.1	62
254	Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis. <i>Oncologist</i> , 2011, 16, 155-164.	3.6	52
255	FDG-PET/CT Compared with Conventional Imaging in the Detection of Distant Metastases of Primary Breast Cancer. <i>Oncologist</i> , 2011, 16, 1111-1119.	3.6	77
256	Improvement of survival and prospect of cure in patients with metastatic breast cancer. <i>Breast Cancer</i> , 2011, 19, 191-199.	2.2	55
257	Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2011, 17, 96-104.	2.4	78
258	Serum HER2 levels determined by two methods in patients with metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2011, 17, 55-62.	2.4	8
259	Information Sharing and Case Conference Among the Multidisciplinary Team Improve Patients'™ Perceptions of Care. <i>Open Nursing Journal</i> , 2011, 5, 79-85.	0.4	14
260	Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. <i>Journal of Neuro-Oncology</i> , 2010, 100, 449-457.	2.7	17
261	Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 351-375.	169.1	294
262	Targeted therapy in inflammatory breast cancer. <i>Cancer</i> , 2010, 116, 2758-2759.	4.4	10
263	Differential Radiosensitizing Effect of Valproic Acid in Differentiation Versus Self-Renewal Promoting Culture Conditions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 889-895.	0.7	38
264	Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer. <i>Breast Journal</i> , 2010, 16, 327-330.	1.5	29
265	PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase. <i>Clinical Cancer Research</i> , 2010, 16, 1802-1811.	6.4	39
266	¹⁸ F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1213-1218.	6.6	52
267	Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor-Expressing Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3090-3099.	1.7	18
268	ABC conceptual model of effective multidisciplinary cancer care. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 544-547.	25.3	17
269	Is High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer Patients a Done Deal?. <i>Women's Health</i> , 2010, 6, 481-485.	1.6	4
270	Future directions of bone-targeted therapy for metastatic breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 641-651.	25.3	89

#	ARTICLE	IF	CITATIONS
271	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 125, 785-795.	2.5	55
272	Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. <i>Journal of Cancer</i> , 2010, , 80-92.	2.7	201
273	Lapatinib in the Treatment of Breast Cancer. <i>Clinical Medicine Therapeutics</i> , 2009, 1, .	0.1	0
274	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6639-6648.	6.4	103
275	A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2375-2382.	1.7	32
276	Interleukin-2 and granulocyte macrophage colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. <i>International Journal of Hematology</i> , 2009, 90, 627-634.	1.6	4
277	Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. <i>Cancer Science</i> , 2009, 100, 2275-2282.	4.0	46
278	Circulating Tumor Cells and [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3303-3311.	17.1	125
279	Receiving Information on Fertility- and Menopause-Related Treatment Effects among Women Who Undergo Hematopoietic Stem Cell Transplantation: Changes in Perceived Importance Over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1465-1474.	1.5	36
280	Pilot Study of Targeted Skeletal Radiation Therapy for Bone-Only Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, 173-177.	2.4	9
281	Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. <i>Breast Cancer Research</i> , 2009, 11, .	5.0	66
282	Molecular targets for treatment of inflammatory breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 387-394.	25.3	49
283	Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. <i>Lancet Oncology</i> , The, 2009, 10, 606-614.	21.9	152
284	Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. <i>Future Oncology</i> , 2009, 5, 1585-1603.	2.4	49
285	The Medical Treatment of Inflammatory Breast Cancer. <i>Seminars in Oncology</i> , 2008, 35, 64-71.	1.9	32
286	PEA-15 Induces Autophagy in Human Ovarian Cancer Cells and Is Associated with Prolonged Overall Survival. <i>Cancer Research</i> , 2008, 68, 9302-9310.	0.6	61
287	Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1846-1850.	1.7	72
288	Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. <i>Haematologica</i> , 2008, 93, 257-264.	4.3	117

#	ARTICLE	IF	CITATIONS
289	Stem Cell Transplantation for Metastatic and High-Risk Nonmetastatic Breast Cancer: A Novel Treatment Approach. , 2008, , 387-410.		0
290	Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nature Clinical Practice Oncology, 2008, 5, 78-89.	0.0	26
291	Leukemia-Associated Primary Granule Proteins (PGPs) Elastase-2 and Proteinase-3 Are Aberrantly Expressed in Solid Tumors: A Potential Therapeutic Target for PR1-Directed Immunotherapy. Blood, 2008, 112, 5440-5440.	1.0	1
292	Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt. Cancer Research, 2007, 67, 5779-5788.	0.6	99
293	Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Molecular Cancer Therapeutics, 2007, 6, 2168-2177.	1.7	65
294	Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Molecular Cancer Therapeutics, 2007, 6, 227-235.	1.7	22
295	Whatâ€™s Past Is Prologue: Lessons Learned and the Need for Further Development of Allogeneic Hematopoietic Stem Cell Transplantation for Renal Cell Carcinoma. Biology of Blood and Marrow Transplantation, 2007, 13, 31-33.	1.5	10
296	Natural History of Metastatic Renal Cell Carcinoma in Patients Who Underwent Consultation for Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 975-985.	1.5	3
297	Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Research, 2007, 9, .	5.0	5
298	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. Clinical Breast Cancer, 2007, 7, 34-42.	2.4	133
299	Inflammatory breast cancer (IBC) and patterns of recurrence. Cancer, 2007, 110, 1436-1444.	4.4	177
300	Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. Blood, 2007, 110, 620-620.	1.0	5
301	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. Blood, 2007, 110, 48-48.	1.0	0
302	Trials and Tribulations in Developing Clinical Trials of Gene Therapy. , 2007, , 387-398.		0
303	Prognostic Value of Nodal Ratios in Node-Positive Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2910-2916.	17.1	166
304	In Reply:. Journal of Clinical Oncology, 2005, 23, 4803-4803.	17.1	0
305	Bcl-2 Antisense Oligonucleotide Overcomes Resistance to E1A Gene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model. Cancer Research, 2005, 65, 8406-8413.	0.6	26
306	Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. Molecular Cancer Therapeutics, 2005, 4, 1039-1046.	1.7	16

#	ARTICLE	IF	CITATIONS
307	Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint. <i>Cancer Research</i> , 2004, 64, 2502-2508.	0.6	214
308	Graft-versus-Breast Cancer Effect by Allogeneic Hematopoietic Stem-Cell Transplantation: A Possible New Frontier. <i>Journal of Clinical Oncology</i> , 2004, 22, 3846-3847.	17.1	2
309	Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin®) conjugated polyethylenimine. <i>Journal of Controlled Release</i> , 2004, 97, 357-369.	11.3	129
310	Bone Imaging in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2942-2953.	17.1	530
311	The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 794-804.	1.5	22
312	Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 330-340.	1.5	6
313	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. <i>Blood</i> , 2003, 102, 3829-3836.	1.0	129
314	Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. <i>British Journal of Haematology</i> , 2002, 119, 131-134.	2.7	61
315	Cationic Liposome-Mediated E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 3422-3433.	17.1	184
316	Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. <i>Blood</i> , 2001, 97, 631-637.	1.0	526
317	E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. <i>Breast Cancer</i> , 2001, 8, 285-293.	2.2	20
318	Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. <i>Transplant Infectious Disease</i> , 2001, 3, 29-33.	2.2	4
319	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2001, 67, 227-233.	6.3	23
320	High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends. <i>Clinical Breast Cancer</i> , 2000, 1, 197-209.	2.4	6
321	ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION AS ADOPTIVE IMMUNOTHERAPY. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1041-1057.	2.4	44
322	Primary malignant teratoma of the thyroid gland: Report and discussion of two cases. , 1998, 20, 649-653.		11
323	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. <i>Oncogene</i> , 1997, 15, 953-960.	6.6	80
324	Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 321-329.	2.3	218